EUCTR2015-002342-30-AT进行中（未招募）1 期
Combining Glucagon and Insulin Infusion with Glucose Sensing in Subcutaneous Adipose Tissue of Type 1 Diabetes Patients
Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel0 个研究点目标入组 8 人开始时间: 2015年6月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Type 1 diabetes treated with CSII
- •- 18 to 64 years of age, both inclusive
- •- HbA1C < 10%
- •- C-peptide < 30 pmol/L
- •- BMI between 20 and 30 kg/m2
- •- Signed informed consent before any study-related
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Severe acute diseases
- •- Clinically overt diabetic complications
- •- Mental incapacity, unwillingness or language barriers
- •precluding adequate understanding or co-operation
- •- Taking of any vasoactive substances or anticoagulation
- •- Diseases of the skin which could interfere with
- •application of catheters as judged by the investigator
- •- Uncontrolled hypertension
- •- Use of a medication that significantly impacts glucose
- •metabolism (e.g. oral or topical steroids) except in the
- •case of a stable state with a minimum duration of at
- •least three months preceding the study as well as under
- •the condition that the state remain stable for the
- •duration of the study
- •- No superficial veins for catheter insertion as judged by
- •the investigator
- •- Pregnancy, breastfeeding, intention of becoming
- •pregnant or not using adequate contraception.
- •- Any disease or condition which the investigator or
- •treating physician feels would interfere with the trial or
- •the safety of the subject
- •- Blood donation within three months preceding the study
- •- Concurrent participation in another study
研究者
相似试验
进行中（未招募）
不适用
Tratamiento combinado de insulina glargina y sitagliptina en pacientes con diabetes tipo 2 no controlados suficientemente con un tratamiento previo con metformina y con insulina glargina o sitagliptina (Extensión del estudio LANTU_C_02761). - EXT_EASIEDiabetes tipo 2 tratada con metformina pero no suficientemente controlada con unt tratamiento previo de metformina y con insulina glargina o sitagliptina.MedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-ESsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-PTsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEEUCTR2008-000521-19-ATsanofi aventis Groupe265
进行中（未招募）
不适用
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1Level: LLTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-NLsanofi aventis Groupe265
进行中（未招募）
1 期
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761). - EXT_EASIEType 2 diabetes treated with metformin and not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptinMedDRA version: 9.1 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-000521-19-GBsanofi aventis Groupe265